Iron as a comorbid factor in chronic viral hepatitis

American Journal of Gastroenterology

Volumn 97, Issue 1, 2002, Pages 1-4

  Bonkovsky, Herbert L ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; IRON CHELATE; LAMIVUDINE; RIBAVIRIN;

CHRONIC HEPATITIS; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; EDITORIAL; FERRITIN BLOOD LEVEL; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; LIVER INJURY; PRIORITY JOURNAL; RISK FACTOR; SYMPTOM; VIRUS HEPATITIS;

EID: 0036142230     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)03952-1     Document Type: Editorial

References (33)

1. A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis
2. Disease-related conditions in relatives of patients with hemochromatosis
3. A novel mutation of HFE explains the classical phenotype of genetic hemochromatosis in a C282Y heterozygote
4. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene
5. Ferroportin mutation in autosomal dominant hemochromatosis: Loss of function, gain in understanding
6. A new mouse liver-specific gene, encoding a protein homologous to human anti-microbial peptide hepcidin, is overexpressed during iron overload
7. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice
8. Hepcidin: A putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease
9. The β-thalassemias
10. Iron as a carcinogen
11. Iron in liver diseases other than hemochromatosis
12. Role of HFE gene mutations in liver disease other than hereditary hemochromatosis
13. Iron-induced liver injury
14. Changes in serum iron levels due to infection with hepatitis B virus
15. Measurements of iron status in patients with chronic hepatitis
16. Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases
17. Iron and chronic viral hepatitis
18. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C
19. A pilot randomized, controlled trial of the effect of iron depletion on long term response to alpha-interferon in patients with chronic hepatitis C
20. Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial
21. Iron depletion and interferon therapy: A multicenter randomized controlled trial in untreated non-cirrhotic patients with chronic hepatitis C
22. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multi-center, prospective, randomized, controlled trial
23. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron
24. Iron stores, response to interferon therapy, and effects of iron depletion in chronic hepatitis C
25. The use of desferrioxamine infusion to enhance the response rate to interferon alpha treatment of chronic viral hepatitis
26. ®) in combination with ribavirin: Efficacy and safety results from phase III, randomized, actively -controlled, multicenter study
27. Peginterferon alfa-2B plus ribavirin compared to interferon alfa-2B plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial
28. Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C
29. Phlebotomy lowers serum ALT and alphafetoprotein levels in patients with chronic hepatitis C
30. Long-term effect of iron removal on chronic hepatitis C
31. Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis
32. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C
33. Retreatment of interferon and interferon-ribavirin non-responders with PEG interferon alpha-2a and ribavirin: Initial results from the lead-in phase of the HALT-C Trial